Quick Recap
Endocrine & Metabolic System, Protocol 4/9. Companion to Thyroid Storm (prior protocol) — shares the critical principle of stress-dose steroids preceding hormone-axis manipulation.
1. Definition & Diagnosis
Myxedema coma = the severe, decompensated endpoint of hypothyroidism in a critically ill patient — hypothermia, hypoventilation, bradycardia, hypotension, and hyponatremia can all be contributed to or worsened by severe hypothyroidism when it coexists with other critical illness.
Diagnostic testing: plasma TSH and free T4. Even MILD primary hypothyroidism causes elevated TSH — a normal plasma TSH EXCLUDES primary hypothyroidism. Plasma TSH >20 mIU/L establishes primary hypothyroidism; milder TSH elevations usually indicate primary hypothyroidism but can also occur TRANSIENTLY during recovery from severe nonthyroidal illness — interpret a mildly elevated TSH in a recovering critically ill patient with appropriate caution rather than reflexively diagnosing hypothyroidism.
Low free T4 + NON-elevated TSH pattern: could represent secondary (pituitary/hypothalamic) hypothyroidism, but in critically ill patients this pattern is MORE LIKELY to represent functional suppression of the TSH/T4 axis by the nonthyroidal illness itself ("sick euthyroid syndrome"/nonthyroidal illness syndrome) rather than true secondary hypothyroidism. If the patient has clinical findings potentially attributable to hypothyroidism, START EMPIRIC T4 treatment and REASSESS the diagnosis after recovery — otherwise, observe with periodic TSH/free T4 monitoring to see whether the pattern resolves spontaneously with recovery from the underlying illness.
2. Clinical Findings
Common (any hypothyroidism): cold intolerance, fatigue, somnolence, constipation, weight gain, slow tendon reflexes, nonpitting edema (myxedema), dry skin.
Seen primarily in SEVERE hypothyroidism (myxedema coma): hypothermia, bradycardia, hypoventilation, hypotension, hyponatremia, pericardial or pleural effusion.
Each of these physiologic abnormalities should ALSO be treated in the STANDARD fashion for that specific problem (e.g., standard hypothermia rewarming, standard hypotension workup/management) since they are RARELY due to hypothyroidism alone — do not assume thyroid hormone repletion will resolve these derangements on its own or attribute them entirely to the thyroid diagnosis; treat each abnormality on its own merits in parallel.
3. Etiology
>90% of cases are PRIMARY hypothyroidism — most often chronic lymphocytic (Hashimoto) thyroiditis, or iatrogenic (post-radioactive iodine therapy or thyroidectomy).
Drug-induced causes: iodine excess (amiodarone, iodinated contrast media — note these agents can cause EITHER hyper- or hypothyroidism depending on the patient's underlying thyroid status and baseline iodine consumption), checkpoint inhibitors, lithium, interferon alpha, interleukin-2/other immunomodulatory drugs (these last several may cause a TRANSIENT thyrotoxicosis before progressing to hypothyroidism — the same drug class caveat noted in the Thyroid Storm protocol's etiology table, worth cross-referencing since these agents can produce either endpoint of the thyroid spectrum).
Secondary hypothyroidism (pituitary/hypothalamic disorder) is usually clinically apparent due to OTHER manifestations of the underlying pituitary/hypothalamic disease, distinguishing it from the more common primary etiologies.
4. Immediate Stabilization (ABCDE)
Airway/Breathing: hypoventilation is a recognized severe-hypothyroidism finding — monitor closely, support ventilation per standard respiratory failure principles if significant (see Acute Respiratory Failure protocol, Respiratory System) rather than assuming thyroid repletion alone will resolve it acutely.
Circulation: hypotension and bradycardia both require standard workup/management in parallel with thyroid-specific therapy; treat hypothermia with standard rewarming techniques.
Disability: hyponatremia should be actively assessed and managed per standard principles (see Severe Electrolyte Disorders protocol) — not assumed to resolve with T4 alone in the acute phase.
Checklist:
5. Emergency Therapy — The Critical Sequencing Rule
Stress-dose hydrocortisone MUST be given PRIOR TO thyroid hormone repletion — this is the single most important safety principle in this protocol, directly parallel to (and for a related mechanistic reason as) the iodine-after-thionamide sequencing rule in the Thyroid Storm protocol. Rationale: adrenal insufficiency may coexist with chronic autoimmune thyroiditis (both being autoimmune endocrinopathies, sometimes as part of polyglandular autoimmune syndrome), and administering thyroid hormone to a patient with UNRECOGNIZED, untreated adrenal insufficiency can PRECIPITATE ADRENAL CRISIS — thyroid hormone accelerates cortisol metabolism/clearance and increases metabolic demand, unmasking or worsening an underlying cortisol deficiency that was previously being tolerated at a lower metabolic rate.
Dosing:
Agent | Dosing |
Thyroxine (levothyroxine) | Consider a loading dose of 200-400 mcg IV, then 1.2 mcg/kg IV q24h until oral intake is possible |
Alternative reference dosing | 200-400 mcg IV as a slow bolus, then 50-100 mcg IV q24h |
Hydrocortisone | 100 mg IV q8h — given FIRST, before or at initiation of thyroxine |
Monitoring during treatment: vital signs and cardiac rhythm must be closely monitored, since thyroid hormone repletion may EXACERBATE UNDERLYING HEART DISEASE — rapid correction of a chronically hypothyroid, hypometabolic cardiovascular state can precipitate myocardial ischemia or arrhythmia in a patient with unrecognized/limited cardiac reserve, particularly in older patients where myxedema coma is more common.
No clinical trials have determined the optimal method for emergency treatment of hypothyroidism — an explicit evidence gap; the regimen above reflects consensus/expert practice rather than RCT-derived dosing, similar to the evidence limitation noted for thyroid storm.
6. Drug Toxicity Profile (Reference)
Agent | Rare toxicities | Notes |
Levothyroxine | Signs/symptoms of hyperthyroidism with excessive dosing: tachycardia, angina pectoris, arrhythmias, MI, heat intolerance, diaphoresis, hyperactivity | Watch for overcorrection, especially in cardiac-compromised patients |
Hydrocortisone | — | Short-term: hyperglycemia, mood changes, insomnia, GI irritation, increased appetite. Long-term (less relevant acutely): osteoporosis, acne, thin skin, HPA axis suppression, increased BP, infection risk |
7. Investigations
TSH, free T4 (interpreted per Section 1's nonthyroidal-illness caveats), electrolytes (especially sodium), glucose, cortisol/ACTH stimulation test if adrenal insufficiency workup is being pursued in parallel (though empiric stress-dose steroid should not be delayed pending these results), ECG/telemetry, blood gas (hypoventilation assessment), blood cultures/infectious workup if a precipitating illness is suspected (similar to the thyroid storm precipitant-search principle).
8. Organ Support
Standard supportive care for each physiologic derangement (rewarming for hypothermia, ventilatory support for hypoventilation, fluid/vasopressor support for hypotension per standard shock workup, sodium correction per the Severe Electrolyte Disorders protocol for hyponatremia); hydrocortisone-then-levothyroxine per the mandatory sequencing above; continuous cardiac monitoring throughout.
9. Consultation Matrix
Consultation | Trigger | Timing |
Endocrinology | All suspected/confirmed myxedema coma | Immediate |
Cardiology | Underlying heart disease, arrhythmia/ischemia risk during repletion | As needed, proactive in older/cardiac-comorbid patients |
10. Monitoring Framework
Continuous cardiac monitoring during thyroid hormone repletion, serial vital signs (temperature, HR, BP, respiratory status), serial TSH/free T4, sodium trend, glucose (given concurrent hydrocortisone's hyperglycemic effect), watch for signs of overcorrection (thyrotoxicosis-like symptoms) or unmasked cardiac ischemia.
11. Complications
Adrenal crisis (if hydrocortisone not given before/with thyroid hormone in a patient with unrecognized coexisting adrenal insufficiency), cardiac ischemia/arrhythmia from repletion in a compromised cardiovascular system, overcorrection/iatrogenic thyrotoxicosis, persistence of hypothermia/hypotension/hyponatremia if these are not separately, actively managed alongside thyroid-specific therapy. Prevention: mandatory hydrocortisone-before-levothyroxine sequencing, close cardiac monitoring during repletion, parallel standard management of each physiologic derangement. Rescue: standard adrenal crisis management if precipitated (see Adrenal Crisis protocol), standard arrhythmia/ischemia management if precipitated.
12. Escalation & De-escalation
Escalate: cardiac ischemia/arrhythmia during repletion -> slow/hold thyroid hormone dosing, manage per Arrhythmias/ACS protocols; persistent hemodynamic instability despite standard measures -> broaden workup for a co-existing precipitant.
De-escalate: vital signs normalizing, TSH/free T4 trending toward normal, hemodynamically stable -> transition to oral levothyroxine once tolerating intake, continue outpatient hydrocortisone taper per endocrinology guidance if adrenal insufficiency confirmed, or discontinue if excluded.
13. ICU Discharge Criteria
Hemodynamically stable, temperature normalized, TSH/free T4 trending appropriately, transitioned to oral levothyroxine, adrenal insufficiency status clarified with an appropriate steroid taper/discontinuation plan, precipitating illness (if identified) treated.
14. Documentation & Medicolegal Checklist
15. Key Guidelines
Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: American Thyroid Association task force. Thyroid. 2014;24(12):1670-1751.
16. Controversies
Explicitly acknowledged by the primary reference source: no clinical trials have determined the optimal method for emergency treatment of hypothyroidism/myxedema coma — current dosing and sequencing practice is consensus-based rather than RCT-derived, given the rarity of this presentation. The precise loading dose of levothyroxine (200-400 mcg cited, with some sources favoring the lower end in elderly/cardiac-comorbid patients) is not tightly standardized and should be individualized for cardiovascular risk.
17. References
- Riek AE. Thyroid Disorders (Hypothyroidism/Myxedema Coma section). Washington Manual of Critical Care, 4th ed, 2025 (Ch. 29).
- Endocrine Disorders drug dosing reference table. Washington Manual of Critical Care, 4th ed, 2025 (Ch. 95).
- Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: American Thyroid Association task force. Thyroid. 2014;24(12):1670-1751.
- Wartofsky L. Myxedema coma. Endocrinol Metab Clin North Am. 2006;35(4):687-698.
See also: Thyroid Storm (Endocrine & Metabolic System) for the companion hyperthyroid emergency and its parallel critical sequencing rule; Adrenal Crisis (Endocrine & Metabolic System) for full adrenal insufficiency management if unmasked; Severe Electrolyte Disorders for hyponatremia management.